Steven RPh - Transgene VP Officer
| TNG Stock | EUR 0.84 0.02 2.44% |
Insider
Steven RPh is VP Officer of Transgene SA
| Age | 61 |
| Address | 400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405 |
| Phone | 33 3 88 27 91 00 |
| Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.4935) % which means that it has lost $0.4935 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.2048) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.69. The current year's Return On Capital Employed is expected to grow to -1.38. At present, Transgene's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.7 M, whereas Total Assets are forecasted to decline to about 46.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gavin Sy | Abionyx Pharma SA | N/A | |
| Brangre Vasseur | OSE Pharma SA | N/A | |
| Dr MBA | Cellectis | 46 | |
| Pr MBA | Abionyx Pharma SA | 76 | |
| Marc Bonneville | Innate Pharma | 66 | |
| Denis Lucquin | Abionyx Pharma SA | N/A | |
| Pascal Caisey | Genfit SA | 58 | |
| Vincent Bastide | Bastide Le Confort | N/A | |
| Jean Epinat | Cellectis | N/A | |
| Mondher MD | Innate Pharma | 65 | |
| Pascalyne Wilson | Cellectis | N/A | |
| Pr Staels | Genfit SA | 63 | |
| Nawal Ouzren | Sensorion SA | 48 | |
| Marc Riviere | Abionyx Pharma SA | N/A | |
| Olivier MBA | Adocia | 56 | |
| PierreMarie Varachaud | Bastide Le Confort | N/A | |
| Petra Zalabak | Guerbet S A | N/A | |
| Valerie Cros | Cellectis | N/A | |
| Renee Benghozi | Abionyx Pharma SA | N/A | |
| Arnaud Fayolle | Bastide Le Confort | N/A | |
| JeanLouis Dasseux | Abionyx Pharma SA | 59 | |
Management Performance
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.49 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JeanPhilippe Del, VP CFO | ||
| Christophe PharmD, Chief VP | ||
| Maurizio Ceppi, Chief Officer | ||
| Hedi Brahim, CEO Director | ||
| Emmanuelle MD, VP Officer | ||
| LLM JD, General VP | ||
| James MBA, VP Officer | ||
| Maud MD, VP Officer | ||
| Eric Quemeneur, Ex Officer | ||
| Gaelle Stadtler, VP HR | ||
| Christelle Schwoerer, Chief Officer | ||
| Katell Huang, Head Medicine | ||
| Elisabetta Castelli, Director Relations | ||
| Lucie Larguier, Director IR | ||
| Alessandro MD, CEO Board | ||
| Steven RPh, VP Officer | ||
| Simone Steiner, Chief Officer | ||
| Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (3.73) % | ||||
| Current Valuation | 237.19 M | ||||
| Shares Outstanding | 273.91 M | ||||
| Shares Owned By Insiders | 35.38 % | ||||
| Shares Owned By Institutions | 0.31 % | ||||
| Price To Earning | 18.08 X | ||||
| Price To Book | 8.86 X | ||||
| Price To Sales | 29.72 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Transgene Stock
Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.